Copyright © Inderes 2011 - present. All rights reserved.

Aiforia Technologies

1.88 EUR

-3.34 %

2,148 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

-3.34 %
-20.68 %
-24.50 %
-24.50 %
-44.05 %
-48.77 %
-57.22 %
-
-62.85 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
63.34M EUR
Turnover
145.8K EUR
P/E (adj.) (25e)
-4.87
EV/EBIT (adj.) (25e)
-5.53
P/B (25e)
4.8
EV/S (25e)
18.16
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
3.20 EUR
Updated
19.11.2025
Disclaimer
Frans-Mikael Rostedt
Antti Luiro
Antti Luiro, Frans-Mikael Rostedt
Show more
Latest research

Latest analysis report

Released: 19.11.2025

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.3
2026

Annual report '25

2.4
2026

General meeting '26

28.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Without taking a position on the analysis itself, Nuways has a “buy” recommendation for almost every client, “under review” for a few, and a few unfortunate ones have been assigned a “hold”. In Germany, these views are consistently very positive. nuways-ag.com Companies Our research...
2/11/2026, 6:24 PM
by Verneri Pulkkinen
28
Answering my own question: The volume at Fimlab was approx. 1,600 slides in September 2025 and 3,500 in October, and the number is growing. Price per slide taken from the comprehensive report And with a good margin Fimlab is, however, on the smaller end of the won tenders, so you...
2/12/2026, 7:53 AM
by Jekkku
21
Quoting the message rather than responding to it. Now that Aiforia has taken a real beating on the stock market and the valuation has dropped to 66 million, I hope it won’t be bought out on the cheap now. $81m was paid for Paige, and it is clearly behind Aiforia, at least in terms...
2/12/2026, 11:38 AM
by Jekkku
20
I now have a full, good-sized position in Aiforia. At least I interpret this latest -15% as a completely extra “Faron discount.” The stock was already at my buy price even before this. It seems quite promising to me. Many contracts have already been signed, and there’s no reason ...
2/12/2026, 3:24 PM
by JusaVaan
19
Pre-results update. Despite the share price, target €3.80 & Buy Summary: We remain upbeat on Aiforia’s Foundation Engine and its clinical and commercial scalability. Aiforia’s clinical footprint now covers breast, prostate, and lung cancers, strengthened by its new gastric cancer...
2/11/2026, 4:54 PM
by Opa
16
It is certainly possible that deals have also been made below the disclosure threshold. I believe there were a few such deals in H1 as well. If I recall correctly, a few deals were pushed to H2, Lombardy and some other one. Additionally, one would think scanners have been installed...
2/11/2026, 10:48 AM
by Jekkku
5
Well, the latest dip is quite clearly due to Faron (and Optomed). Probably the “retail crowd” got spooked, and many interested in these kinds of stocks may have invested in both, so some “believer” might be selling other suitable holdings to prepare for Faron’s share issue or wants...
2/11/2026, 10:45 AM
by JusaVaan
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.